Biocept Inc. News Releases http://ir.biocept.com/ Biocept Inc. News Releases en Biocept to Present at the 9th Annual LD Micro Invitational Conference on June 4 http://ir.biocept.com/news-releases/news-release-details/biocept-present-9th-annual-ld-micro-invitational-conference-june SAN DIEGO , June 3, 2019 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. Mon, 03 Jun 2019 08:05:00 -0400 Biocept Inc. News Releases 10801 Biocept Awarded Patent in China for its Circulating Tumor Cell Platform Expanding Intellectual Property Estate to 33 Issued Patents Globally http://ir.biocept.com/news-releases/news-release-details/biocept-awarded-patent-china-its-circulating-tumor-cell-platform Newly issued patent in China covers use of antibody cocktails in combination with a microchannel to capture rare cells such as circulating tumor cells (CTCs) from any biological sample of interest SAN DIEGO , May 28, 2019 /PRNewswire/ --  Biocept, Inc . Tue, 28 May 2019 08:05:00 -0400 Biocept Inc. News Releases 10776 Biocept Announces Clinical Validation and Commercial Launch of its Target Selector™ Multi-Gene Liquid Biopsy Panel for Lung Cancer http://ir.biocept.com/news-releases/news-release-details/biocept-announces-clinical-validation-and-commercial-launch-its Biocept now positioned as the only commercial liquid biopsy provider that offers single-biomarker testing, tumor-specific panels, and circulating tumor cell analysis SAN DIEGO , May 20, 2019 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed Mon, 20 May 2019 08:05:00 -0400 Biocept Inc. News Releases 10751 Biocept Reports First Quarter 2019 Financial Results http://ir.biocept.com/news-releases/news-release-details/biocept-reports-first-quarter-2019-financial-results - Revenues increased 27% compared to the first quarter of 2018 - Billable samples grew 7% year over year, and increased 23% vs. the fourth quarter of 2018 - Commercial gains driven primarily by broadened pathology partnership service - Conference call begins at 4:30 p.m. Wed, 08 May 2019 16:05:00 -0400 Biocept Inc. News Releases 10726 Biocept to Release First Quarter 2019 Financial Results and Host Investor Conference Call on May 8, 2019 http://ir.biocept.com/news-releases/news-release-details/biocept-release-first-quarter-2019-financial-results-and-host SAN DIEGO , May 1, 2019 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve the outcomes of patients diagnosed with cancer, announces Wed, 01 May 2019 08:05:00 -0400 Biocept Inc. News Releases 10716 Biocept Reports 2018 Fourth Quarter and Full Year Financial Results http://ir.biocept.com/news-releases/news-release-details/biocept-reports-2018-fourth-quarter-and-full-year-financial Progress made implementing the Company's commercial strategy highlighted by 7% sequential quarterly growth in billable test volume in the fourth quarter of 2018 compared to the third quarter of 2018 Capitalized to deliver on key initiatives in 2019 including growth from pathology partnership and Thu, 28 Mar 2019 16:05:00 -0400 Biocept Inc. News Releases 10661 Biocept Broadens Commercial Focus of its Target Selector Liquid Biopsy Platform to Include Urology Market Segment http://ir.biocept.com/news-releases/news-release-details/biocept-broadens-commercial-focus-its-target-selector-liquid Expansion of Biocept's EmpowerTC™ offering now includes predictive and prognostic biomarker testing to aid pathologists and urologists in the management of patients diagnosed with prostate cancer SAN DIEGO , March 26, 2019 /PRNewswire/ --  Biocept, Inc. Tue, 26 Mar 2019 08:05:00 -0400 Biocept Inc. News Releases 10656 Biocept to Release 2018 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 28, 2019 http://ir.biocept.com/news-releases/news-release-details/biocept-release-2018-fourth-quarter-and-full-year-financial SAN DIEGO , March 21, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release financial Thu, 21 Mar 2019 08:05:00 -0400 Biocept Inc. News Releases 10646 Biocept Awarded Patent in Japan for the Capture of Rare Cells Including CTCs from Any Biological Sample of Interest with A Microchannel Device http://ir.biocept.com/news-releases/news-release-details/biocept-awarded-patent-japan-capture-rare-cells-including-ctcs Biocept expands intellectual property position to 32 issued patents globally for its highly sensitive methods for detecting cancer biomarkers in blood and other specimen types SAN DIEGO , March 18, 2019 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy Mon, 18 Mar 2019 08:05:00 -0400 Biocept Inc. News Releases 10641 Biocept Announces Pricing of $8.2 Million Registered Direct Offering http://ir.biocept.com/news-releases/news-release-details/biocept-announces-pricing-82-million-registered-direct-offering SAN DIEGO , March 15, 2019 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has Fri, 15 Mar 2019 09:00:00 -0400 Biocept Inc. News Releases 10626